Liquid Biopsy Market Size and Outlook 2030

Report Description

Forecast Period	2026-2030
Market Size (2024)	USD 4.93 Billion
CAGR (2025-2030)	12.50%
Fastest Growing Segment	Next Generation Sequencing (NGS)
Largest Market	North America
Market Size (2030)	USD 9.99 Billion

Market Overview

The Global Liquid Biopsy Market, valued at USD 4.93 Billion in 2024, is projected to experience a CAGR of 12.50% to reach USD 9.99 Billion by 2030. The global liquid biopsy market focuses on diagnostic tests that detect and analyze genetic material, such as circulating tumor DNA and circulating tumor cells, present in bodily fluids, primarily blood. This non-invasive approach facilitates early cancer detection, treatment monitoring, and identification of genetic mutations, offering advantages over traditional tissue biopsies. The market's growth is primarily driven by the escalating global cancer incidence, with the International Agency for Research on Cancer reporting an estimated 19.3 million new cancer cases worldwide in 2022. Additional key drivers include the increasing demand for less invasive diagnostic procedures and ongoing technological advancements in assay development and genomic sequencing platforms.

However, a notable challenge that could impede market expansion is the prevailing concern regarding test accuracy and the absence of universally standardized procedures across various platforms. This can contribute to potentially inaccurate outcomes, affecting the overall clinical utility and broader adoption of liquid biopsy tests.

Key Market Drivers

The global liquid biopsy market's expansion is fundamentally propelled by the escalating worldwide cancer burden. The significant increase in cancer diagnoses necessitates accessible, less invasive diagnostic and monitoring tools. According to the World Health Organization and the International Agency for Research in Cancer, in their February 2024 news release "Global cancer burden growing, amidst mounting need for services", an estimated 20 million new cancer cases occurred worldwide in 2022. This prevalence drives demand for technologies enabling early detection, treatment guidance, and disease monitoring with minimal patient discomfort. Increasing regulatory and clinical validation supports market penetration. According to the Association for Diagnostics & Laboratory Medicine, in their November 2024 article "FDA approves next-generation cancer biomarker test and companion diagnostics", the FDA approved FoundationOne Liquid CDx as a companion diagnostic for AstraZeneca's Lynparza in combination with other therapies for BRCA-mutated metastatic castration-resistant prostate cancer, demonstrating expanding clinical utility.

Advancements in genomic sequencing significantly contribute to the liquid biopsy market's growth by enhancing biomarker detection sensitivity and specificity. Continuous improvements in next-generation sequencing and digital PCR assays identify minute quantities of tumor-derived genetic material in bodily fluids, improving diagnostic accuracy. For instance, according to an article in Frontline Genomics in February 2024 titled "The Latest Developments in Sequencing Technologies", Illumina launched its Complete Long Reads for NovaSeq in March 2023, designed to generate longer, more contiguous sequencing reads, yielding comprehensive genetic insights from liquid biopsy samples. These advancements establish liquid biopsy as a more reliable and powerful tool for precision oncology, enabling detailed genetic profiling that informs targeted therapies and personalized treatment plans, moving beyond traditional tissue biopsy limitations.

Download Free Sample Report

Key Market Challenges

The prevailing concern regarding test accuracy and the absence of universally standardized procedures across various platforms presents a significant impediment to the growth of the global liquid biopsy market. The lack of consistent protocols for assay development, validation, and reporting contributes to variable test performance and potentially inaccurate outcomes. This directly undermines the confidence of healthcare providers in integrating liquid biopsy into routine clinical practice, slowing its broader adoption.

For example, according to a 2024 International Association for the Study of Lung Cancer Global Survey, 26% of surveyed institutions were unaware of any biomarker testing guidelines, while only 54% utilized the comprehensive CAP-IASLC-AMP guidelines. Such discrepancies in guideline awareness and implementation highlight the fragmented landscape of liquid biopsy utilization. This variability complicates comparative analysis across different platforms and laboratories, making it difficult for clinicians to fully trust and rely on the results for critical treatment decisions. Consequently, the market experiences slower expansion as stakeholders exercise caution due to these unresolved issues in standardization and perceived reliability.

Key Market Trends

Multi-analyte and multi-cancer screening development is significantly driving the global liquid biopsy market by enabling the simultaneous detection of various cancer types from a single blood sample. This trend promotes broader, earlier cancer identification, enhancing preventative care and treatment outcomes. In March 2024, the National Institutes of Health launched its Cancer Screening Research Network to evaluate multi-cancer early detection tests, initiating a Vanguard Study enrolling up to 24,000 participants. This highlights national commitment to validating advanced diagnostics. Further demonstrating progress, Exai Bio presented data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, showing its RNA- and AI-based platform achieved 87% overall stage I sensitivity across eight cancer types at 95% specificity in a 3,300 subject study.

The integration of Artificial Intelligence and Machine Learning for enhanced diagnostics profoundly influences the liquid biopsy market by optimizing data analysis and improving diagnostic precision. These computational techniques process vast, complex biomarker data to uncover subtle disease indicators, leading to faster, more accurate diagnoses. The American Association for Cancer Research (AACR) reported in its 2025 Cancer Progress Report that between July 1, 2024, and June 30, 2025, the U. S. Food and Drug Administration approved several AI-powered devices and software tools for aiding in cancer risk prediction, diagnosis, and early detection, underscoring regulatory acceptance. Illustrating this impact, researchers from the Johns Hopkins Kimmel Cancer Center, in a June 2024 study published in Cancer Discovery, developed an AI-powered liquid biopsy demonstrating a 99.8% negative predictive value for early lung cancer detection by identifying specific DNA fragment patterns.

Segmental Insights

The Next Generation Sequencing (NGS) segment is a key growth driver in the Global Liquid Biopsy Market, primarily due to its ability to perform comprehensive genomic profiling of circulating tumor DNA (ctDNA). This technology offers unparalleled sensitivity and accuracy, enabling the detection of multiple genetic mutations simultaneously, including low-frequency and rare variants crucial for early cancer detection and monitoring minimal residual disease. Furthermore, NGS facilitates the selection of highly specific and personalized treatment strategies for patients, transforming precision oncology by overcoming the limitations of traditional tissue biopsies and aiding in the development of companion diagnostics. This comprehensive insight and advanced diagnostic capability are propelling its rapid adoption.

Regional Insights

North America leads the global liquid biopsy market due to several distinct advantages. The region benefits from a high prevalence of cancer, which drives demand for advanced diagnostic solutions. This is coupled with a robust healthcare infrastructure and substantial investments in research and development. Furthermore, North America exhibits rapid adoption of innovative diagnostic technologies and boasts a favorable regulatory landscape, including proactive approvals by the U. S. Food and Drug Administration (FDA) for novel liquid biopsy tests. The presence of numerous key biotechnology companies and supportive organizations, such as the American Society of Clinical Oncology (ASCO), further consolidates its market leadership.

Recent Developments

In October 2025, AccuGenomics and 1Cell.Ai, both US-based companies, established a strategic collaboration aimed at providing advanced liquid biopsy testing for the Asian market. This partnership facilitates the delivery of ultra-sensitive, clinically actionable liquid biopsy solutions through 1Cell.Ai’s clinical laboratory in India. The initiative is designed to enhance cancer diagnostics accuracy and accessibility across Asia by integrating AccuGenomics’ quality standards with 1Cell.Ai’s multi-omic precision oncology platform. The companies intend to process tens of thousands of patient samples, with plans for future expansion into the United States market.

In April 2025, Guardant Health announced a strategic collaboration with Pfizer to advance the development and commercialization of Pfizer’s oncology therapies utilizing Guardant’s Infinity™ smart liquid biopsy platform. This multi-year global agreement will incorporate Guardant’s liquid biopsy tests into Pfizer’s clinical studies worldwide. The collaboration also involves evaluating the clinical utility of circulating tumor DNA (ctDNA) levels as a surrogate endpoint for monitoring therapy response and conducting related blood-based epigenomic analyses. Furthermore, Pfizer will gain access to Guardant’s liquid biopsy tests for clinical trials in China.

In February 2025, Labcorp announced the clinical availability of Labcorp® Plasma Complete™, a new liquid biopsy test for patients diagnosed with advanced solid tumors. This circulating tumor DNA (ctDNA)-based comprehensive genomic profiling solution empowers oncologists to make personalized treatment decisions based on insights from a simple blood draw. The test demonstrated high clinical accuracy and reliability in validation studies, offering a reportable range with a variant allele frequency as low as 0.1% and a specificity exceeding 99.99%. This development expands Labcorp's oncology portfolio, supporting tailored patient care.

In September 2024, Novigenix, a company specializing in precision medicine and liquid biopsy technologies, presented its multimodal liquid biopsy approach at the European Society for Medical Oncology (ESMO) conference. This innovative method integrates advanced immune profiling with cell-free DNA (cfDNA) analysis to offer a comprehensive view of tumor and immune signals. The technology, which builds upon data that earned Novigenix the MATWIN award for "Best 2024 Technology Innovation" in oncology, aims to improve the accuracy of predicting patient outcomes and guiding personalized cancer therapies.

Key Market Players

F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific, Inc.
PerkinElmer Inc.
LungLife AI, Inc.
Illumina, Inc.
QIAGEN NV
NeoGenomics Laboratories, Inc.
Myriad Genetics, Inc.
Bio-Rad Laboratories, Inc.
Guardant Health Inc.
Natera, Inc.
Sysmex Corporation
Abcodia Ltd.
Dxcover Limited

By Offering	By Technology	By Workflow	By Sample	By Circulating Biomarkers	By Application	By End User	By Region
Testing Services Kits Platform Other Consumables	Polymerase Chain Reaction (PCR) Next Generation Sequencing (NGS) Others	Sample Preparation Library Preparation Sequencing Data Analysis & Management	Blood Urine Saliva Others	Circulating Tumor Cells (CTCs) Cell-free Nucleic Acids Exosomes & Extracellular Vesicles	Oncological Non-oncological	Clinical Laboratories Academic & Research Institutes Pharmaceutical & Biotechnology Companies	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Liquid Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Liquid Biopsy Market, By Offering:

o Testing Services

o Kits

o Platform

o Other Consumables

Liquid Biopsy Market, By Technology:

o Polymerase Chain Reaction (PCR)

o Next Generation Sequencing (NGS)

o Others

Liquid Biopsy Market, By Workflow:

o Sample Preparation

o Library Preparation

o Sequencing

o Data Analysis & Management

Liquid Biopsy Market, By Sample:

o Blood

o Urine

o Saliva

o Others

Liquid Biopsy Market, By Circulating Biomarkers:

o Circulating Tumor Cells (CTCs)

o Cell-free Nucleic Acids

o Exosomes & Extracellular Vesicles

Liquid Biopsy Market, By Application:

o Oncological

o Non-oncological

Liquid Biopsy Market, By End User:

o Clinical Laboratories

o Academic & Research Institutes

o Pharmaceutical & Biotechnology Companies

Liquid Biopsy Market, By Region:

o North America

§ United States

§ Canada

§ Mexico

o Europe

§ France

§ United Kingdom

§ Italy

§ Germany

§ Spain

o Asia Pacific

§ China

§ India

§ Japan

§ Australia

§ South Korea

o South America

§ Brazil

§ Argentina

§ Colombia

o Middle East & Africa

§ South Africa

§ Saudi Arabia

§ UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Liquid Biopsy Market.

Available Customizations:

Global Liquid Biopsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Liquid Biopsy Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Liquid Biopsy Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Offering (Testing Services, Kits, Platform, Other Consumables)

5.2.2. By Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Others)

5.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)

5.2.4. By Sample (Blood, Urine, Saliva, Others)

5.2.5. By Circulating Biomarkers (Circulating Tumor Cells (CTCs), Cell-free Nucleic Acids, Exosomes & Extracellular Vesicles)

5.2.6. By Application (Oncological, Non-oncological)

5.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)

5.2.8. By Region

5.2.9. By Company (2024)

5.3. Market Map

6. North America Liquid Biopsy Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Offering

6.2.2. By Technology

6.2.3. By Workflow

6.2.4. By Sample

6.2.5. By Circulating Biomarkers

6.2.6. By Application

6.2.7. By End User

6.2.8. By Country

6.3. North America: Country Analysis

6.3.1. United States Liquid Biopsy Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Offering

6.3.1.2.2. By Technology

6.3.1.2.3. By Workflow

6.3.1.2.4. By Sample

6.3.1.2.5. By Circulating Biomarkers

6.3.1.2.6. By Application

6.3.1.2.7. By End User

6.3.2. Canada Liquid Biopsy Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Offering

6.3.2.2.2. By Technology

6.3.2.2.3. By Workflow

6.3.2.2.4. By Sample

6.3.2.2.5. By Circulating Biomarkers

6.3.2.2.6. By Application

6.3.2.2.7. By End User

6.3.3. Mexico Liquid Biopsy Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Offering

6.3.3.2.2. By Technology

6.3.3.2.3. By Workflow

6.3.3.2.4. By Sample

6.3.3.2.5. By Circulating Biomarkers

6.3.3.2.6. By Application

6.3.3.2.7. By End User

7. Europe Liquid Biopsy Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Offering

7.2.2. By Technology

7.2.3. By Workflow

7.2.4. By Sample

7.2.5. By Circulating Biomarkers

7.2.6. By Application

7.2.7. By End User

7.2.8. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Liquid Biopsy Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Offering

7.3.1.2.2. By Technology

7.3.1.2.3. By Workflow

7.3.1.2.4. By Sample

7.3.1.2.5. By Circulating Biomarkers

7.3.1.2.6. By Application

7.3.1.2.7. By End User

7.3.2. France Liquid Biopsy Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Offering

7.3.2.2.2. By Technology

7.3.2.2.3. By Workflow

7.3.2.2.4. By Sample

7.3.2.2.5. By Circulating Biomarkers

7.3.2.2.6. By Application

7.3.2.2.7. By End User

7.3.3. United Kingdom Liquid Biopsy Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Offering

7.3.3.2.2. By Technology

7.3.3.2.3. By Workflow

7.3.3.2.4. By Sample

7.3.3.2.5. By Circulating Biomarkers

7.3.3.2.6. By Application

7.3.3.2.7. By End User

7.3.4. Italy Liquid Biopsy Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Offering

7.3.4.2.2. By Technology

7.3.4.2.3. By Workflow

7.3.4.2.4. By Sample

7.3.4.2.5. By Circulating Biomarkers

7.3.4.2.6. By Application

7.3.4.2.7. By End User

7.3.5. Spain Liquid Biopsy Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Offering

7.3.5.2.2. By Technology

7.3.5.2.3. By Workflow

7.3.5.2.4. By Sample

7.3.5.2.5. By Circulating Biomarkers

7.3.5.2.6. By Application

7.3.5.2.7. By End User

8. Asia Pacific Liquid Biopsy Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Offering

8.2.2. By Technology

8.2.3. By Workflow

8.2.4. By Sample

8.2.5. By Circulating Biomarkers

8.2.6. By Application

8.2.7. By End User

8.2.8. By Country

8.3. Asia Pacific: Country Analysis

8.3.1. China Liquid Biopsy Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Offering

8.3.1.2.2. By Technology

8.3.1.2.3. By Workflow

8.3.1.2.4. By Sample

8.3.1.2.5. By Circulating Biomarkers

8.3.1.2.6. By Application

8.3.1.2.7. By End User

8.3.2. India Liquid Biopsy Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Offering

8.3.2.2.2. By Technology

8.3.2.2.3. By Workflow

8.3.2.2.4. By Sample

8.3.2.2.5. By Circulating Biomarkers

8.3.2.2.6. By Application

8.3.2.2.7. By End User

8.3.3. Japan Liquid Biopsy Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Offering

8.3.3.2.2. By Technology

8.3.3.2.3. By Workflow

8.3.3.2.4. By Sample

8.3.3.2.5. By Circulating Biomarkers

8.3.3.2.6. By Application

8.3.3.2.7. By End User

8.3.4. South Korea Liquid Biopsy Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Offering

8.3.4.2.2. By Technology

8.3.4.2.3. By Workflow

8.3.4.2.4. By Sample

8.3.4.2.5. By Circulating Biomarkers

8.3.4.2.6. By Application

8.3.4.2.7. By End User

8.3.5. Australia Liquid Biopsy Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Offering

8.3.5.2.2. By Technology

8.3.5.2.3. By Workflow

8.3.5.2.4. By Sample

8.3.5.2.5. By Circulating Biomarkers

8.3.5.2.6. By Application

8.3.5.2.7. By End User

9. Middle East & Africa Liquid Biopsy Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Offering

9.2.2. By Technology

9.2.3. By Workflow

9.2.4. By Sample

9.2.5. By Circulating Biomarkers

9.2.6. By Application

9.2.7. By End User

9.2.8. By Country

9.3. Middle East & Africa: Country Analysis

9.3.1. Saudi Arabia Liquid Biopsy Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Offering

9.3.1.2.2. By Technology

9.3.1.2.3. By Workflow

9.3.1.2.4. By Sample

9.3.1.2.5. By Circulating Biomarkers

9.3.1.2.6. By Application

9.3.1.2.7. By End User

9.3.2. UAE Liquid Biopsy Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Offering

9.3.2.2.2. By Technology

9.3.2.2.3. By Workflow

9.3.2.2.4. By Sample

9.3.2.2.5. By Circulating Biomarkers

9.3.2.2.6. By Application

9.3.2.2.7. By End User

9.3.3. South Africa Liquid Biopsy Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Offering

9.3.3.2.2. By Technology

9.3.3.2.3. By Workflow

9.3.3.2.4. By Sample

9.3.3.2.5. By Circulating Biomarkers

9.3.3.2.6. By Application

9.3.3.2.7. By End User

10. South America Liquid Biopsy Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Offering

10.2.2. By Technology

10.2.3. By Workflow

10.2.4. By Sample

10.2.5. By Circulating Biomarkers

10.2.6. By Application

10.2.7. By End User

10.2.8. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Liquid Biopsy Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Offering

10.3.1.2.2. By Technology

10.3.1.2.3. By Workflow

10.3.1.2.4. By Sample

10.3.1.2.5. By Circulating Biomarkers

10.3.1.2.6. By Application

10.3.1.2.7. By End User

10.3.2. Colombia Liquid Biopsy Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Offering

10.3.2.2.2. By Technology

10.3.2.2.3. By Workflow

10.3.2.2.4. By Sample

10.3.2.2.5. By Circulating Biomarkers

10.3.2.2.6. By Application

10.3.2.2.7. By End User

10.3.3. Argentina Liquid Biopsy Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Offering

10.3.3.2.2. By Technology

10.3.3.2.3. By Workflow

10.3.3.2.4. By Sample

10.3.3.2.5. By Circulating Biomarkers

10.3.3.2.6. By Application

10.3.3.2.7. By End User

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)

12.2. Product Launches (If Any)

12.3. Recent Developments

13. Global Liquid Biopsy Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. F. Hoffmann-La Roche Ltd.

15.1.1. Business Overview

15.1.2. Products & Services

15.1.3. Recent Developments

15.1.4. Key Personnel

15.1.5. SWOT Analysis

15.2. Thermo Fisher Scientific, Inc.

15.3. PerkinElmer Inc.

15.4. LungLife AI, Inc.

15.5. Illumina, Inc.

15.6. QIAGEN NV

15.7. NeoGenomics Laboratories, Inc.

15.8. Myriad Genetics, Inc.

15.9. Bio-Rad Laboratories, Inc.

15.10. Guardant Health Inc.

15.11. Natera, Inc.

15.12. Sysmex Corporation

15.13. Abcodia Ltd.

15.14. Dxcover Limited

16. Strategic Recommendations

17. About Us & Disclaimer

Report Description

Table of content

Figures and Tables

Frequently asked questions

What was the market size of the Global Liquid Biopsy Market in 2024?

Which is the dominating region in the Global Liquid Biopsy Market?

Which is the fastest growing segment in the Global Liquid Biopsy Market?

What is the expected growth rate of the Global Liquid Biopsy Market?